二甲双胍
医学
有机阳离子转运蛋白
药效学
药理学
药物基因组学
单核苷酸多态性
运输机
药品
药代动力学
加药
效力
药物遗传学
糖尿病
基因型
基因
生物
遗传学
内分泌学
体外
作者
Shaoqian Li,Bo Xu,Shangzhi Fan,Bo Kyeong Kang,Lianfu Deng,Danjun Chen,Bo Yang,Fan Tang,Zunbo He,Yong Xue,Jiahao Zhou
标识
DOI:10.1080/17512433.2022.2118714
摘要
Metformin has been recognized as the first-choice drug for type 2 diabetes mellitus (T2DM). The potency of metformin in the treatment of type 2 diabetes has always been in the spotlight and shown significant individual differences. Based on previous studies, the efficacy of metformin is related to the single-nucleotide polymorphisms of transporter genes carried by patients, amongst which a variety of gene polymorphisms of transporter and target protein genes affect the effectiveness and adverse repercussion of metformin.Here, we reviewed the current knowledge about gene polymorphisms impacting metformin efficacy based on transporter and drug target proteins.The reason for the difference in clinical drug potency of metformin can be attributed to the gene polymorphism of drug transporters and drug target proteins in the human body. Substantial evidence shows that genetic polymorphisms in transporters such as organic cation transporter 1 (OCT1) and organic cation transporter 2 (OCT2) affect the glucose-lowering effectiveness of metformin. However, optimization of individualized dosing regimens of metformin is necessary to clarify the role of several polymorphisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI